Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ABALOPARATIDE Cause Post procedural complication? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Post procedural complication have been filed in association with ABALOPARATIDE (Tymlos). This represents 0.1% of all adverse event reports for ABALOPARATIDE.

13
Reports of Post procedural complication with ABALOPARATIDE
0.1%
of all ABALOPARATIDE reports
1
Deaths
7
Hospitalizations

How Dangerous Is Post procedural complication From ABALOPARATIDE?

Of the 13 reports, 1 (7.7%) resulted in death, 7 (53.8%) required hospitalization, and 1 (7.7%) were considered life-threatening.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ABALOPARATIDE. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does ABALOPARATIDE Cause?

Headache (4,048) Nausea (3,134) Dizziness (3,005) Fatigue (2,637) Heart rate increased (2,092) Palpitations (1,730) Arthralgia (1,711) Bone pain (1,360) Back pain (1,229) Pain (1,191)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) RISANKIZUMAB-RZAA (232) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157)

Which ABALOPARATIDE Alternatives Have Lower Post procedural complication Risk?

ABALOPARATIDE vs ABATACEPT ABALOPARATIDE vs ABATACEPT SUBQ /ML ABALOPARATIDE vs ABCIXIMAB ABALOPARATIDE vs ABEMACICLIB ABALOPARATIDE vs ABILIFY

Related Pages

ABALOPARATIDE Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication ABALOPARATIDE Demographics